Skip to main content
. 2022 Jun 1;27(9):740–750. doi: 10.1093/oncolo/oyac082

Table 3.

Univariate correlation with study cohort (multi-agent vs. single-agent vs. no chemotherapy for stage III high-risk).

Chemotherapy type Parametric P-value a
Covariate Statistics Level No chemo N = 10229 Single agent N = 3306 Multi-agent N = 6687
Facility type N (Col %) Community cancer program 1379 (13.48) 410 (12.4) 899 (13.44) <.001
N (Col %) Comprehensive Community cancer program 5134 (50.19) 1639 (49.58) 3240 (48.45)
N (Col %) Academic/research program 2162 (21.14) 787 (23.81) 1640 (24.53)
N (Col %) Integrated network cancer program 1554 (15.19) 470 (14.22) 908 (13.58)
Facility location N (Col %) Northeast 2411 (23.57) 815 (24.65) 1604 (23.99) <.001
N (Col %) South 3370 (32.95) 1038 (31.4) 2140 (32)
N (Col %) Midwest 2815 (27.52) 906 (27.4) 2001 (29.92)
N (Col %) West 1633 (15.96) 547 (16.55) 942 (14.09)
Sex N (Col %) Male 3844 (37.58) 1338 (40.47) 3083 (46.1) <.001
N (Col %) Female 6385 (62.42) 1968 (59.53) 3604 (53.9)
Median income quartiles 2000 N (Col %) <$30 000 1319 (13.2) 398 (12.36) 802 (12.3) .392
N (Col %) $30 000-$34 999 1774 (17.76) 556 (17.27) 1167 (17.9)
N (Col %) $35 000-$45 999 2817 (28.2) 960 (29.81) 1850 (28.38)
N (Col %) ≥$46 000 4079 (40.83) 1306 (40.56) 2699 (41.41)
Median income quartiles 2008-2012 N (Col %) <$38 000 1813 (17.81) 539 (16.38) 1058 (15.89) .024
N (Col %) $38 000-$47 999 2388 (23.45) 776 (23.59) 1559 (23.42)
N (Col %) $48 000-$62 999 2688 (26.4) 923 (28.05) 1862 (27.97)
N (Col %) ≥$63 000 3293 (32.34) 1052 (31.98) 2179 (32.73)
Median income quartiles 2012-2016 N (Col %) <$40,227 1938 (19.19) 584 (17.89) 1128 (17.11) .014
N (Col %) $40 227-50 353 2242 (22.2) 735 (22.52) 1456 (22.08)
N (Col %) $50 354-63 332 2356 (23.33) 816 (25) 1623 (24.62)
N (Col %) ≥$63 333 3563 (35.28) 1129 (34.59) 2386 (36.19)
Urban/rural 2003 N (Col %) Metro 8392 (84.32) 2621 (81.63) 5277 (81.04) <.001
N (Col %) Urban 1075 (10.8) 413 (12.86) 840 (12.9)
N (Col %) Rural 485 (4.87) 177 (5.51) 395 (6.07)
Year of diagnosis N (Col %) 2004-2006 2057 (20.11) 664 (20.08) 1091 (16.32) <.001
N (Col %) 2007-2009 1772 (17.32) 497 (15.03) 1127 (16.85)
N (Col %) 2010-2012 3137 (30.67) 931 (28.16) 2174 (32.51)
N (Col %) 2013-2015 3263 (31.9) 1214 (36.72) 2295 (34.32)
Grade N (Col %) Well differentiated, differentiated, and NOS 475 (4.64) 165 (4.99) 320 (4.79) <.001
N (Col %) Moderately differentiated, moderately well differentiated, and intermediate differentiation 5315 (51.96) 1849 (55.93) 3745 (56)
N (Col %) Poorly differentiated 3839 (37.53) 1107 (33.48) 2264 (33.86)
N (Col %) Undifferentiated, anaplastic 600 (5.87) 185 (5.6) 358 (5.35)
Race N (Col %) White 8980 (88.37) 2903 (88.34) 5852 (88.17) .396
N (Col %) Black 835 (8.22) 257 (7.82) 524 (7.9)
N (Col %) Other 347 (3.41) 126 (3.83) 261 (3.93)
Hispanic ethnicity N (Col %) No 9248 (95.88) 2970 (95.16) 6034 (95.66) .222
N (Col %) Yes 397 (4.12) 151 (4.84) 274 (4.34)
Insurance type N (Col %) Not insured 59 (0.59) 24 (0.73) 30 (0.45) .029
N (Col %) Private insurance 894 (8.87) 327 (10) 662 (10.03)
N (Col %) Government insurance 9124 (90.54) 2920 (89.27) 5906 (89.51)
Surgical margins N (Col %) Negative 8382 (82.94) 2888 (88.32) 5778 (87.36) <.001
N (Col %) Positive 1724 (17.06) 382 (11.68) 836 (12.64)
Charlson-Deyo scores N (Col %) 0 6040 (59.05) 2026 (61.28) 4543 (67.94) <.001
N (Col %) 1 2653 (25.94) 904 (27.34) 1572 (23.51)
N (Col %) ≥2 1536 (15.02) 376 (11.37) 572 (8.55)
Tumor size N (Col %) ≤2 cm 297 (2.96) 93 (2.87) 234 (3.58) <.001
N (Col %) 2-4 cm 2826 (28.2) 1020 (31.45) 2225 (34.05)
N (Col %) >4 cm 6899 (68.84) 2130 (65.68) 4076 (62.37)
Age at diagnosis N 10 229 3306 6687 <.001
Mean 82.19 79.17 75.65
Median 83 79 75
Min 70 70 70
Max 90 90 90
SDv 5.89 5.23 4.34

The parametric P-value is calculated by ANOVA for numerical covariates and χ2 test for categorical covariates.